ing human Hsp72 was constructed using the AdEasy system (Qbiogene, Carlsbad, CA, USA). The cDNA for Hsp72 (approved gene symbol HSPA1A) was amplified by reverse transcription-polymerase chain reaction (PCR) using total RNA extracted from HeLa cells that were previously heat shocked at 42°C for 30 minutes. The amplified product was cloned into the pShuttle-CMV vector and verified by sequencing. The vector was then transfomed into Escherichia coli strain BJ5183 together with the pAdEasy-1 vector that contains the entire adenovirus serotype 5 genome except the E1 and E3 regions. The recombinant adenoviral constructs were selected and transfected into the HEK-293 packaging cell line to produce viral particles. Viral titers were determined by limiting dilution on 293 cells and the absence of the E1a gene in the viral constructs was confirmed by PCR.
Cell culture
The rat retinal ganglion cell line, RGC-5, was originally provided as a gift from Dr. Neeraj Agarwal (University of North Texas Health Science Center, Fort Worth, TX, USA). RGC-5 cells were maintained in medium containing Dulbecco's modified Eagle's medium (Life Technologies, Rockville, MD, USA), 10% fetal bovine serum, and antibiotics at 37°C in a humidified 5% CO 2 -95% air atmosphere.
Western blot analysis
RGC-5 cells grown to 70% confluence in a 24-well plate were transduced with a recombinant adenovirus expressing Hsp72 for 2 hours at a multiplicity of infection (MOI) of 5 to 50 plaque forming units (pfu) per cell. Forty-eight hours after transduction, adherent cells were lysed with 0.4 mL of 1 × Laemmli sample buffer and boiled for 5 minutes. The protein samples were resolved by sodium dodesyl sulfate polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was blocked with 5% skim milk overnight, incubated for 2 hours with anti-Hsp72 antibody (Stressgen, Victoria, Canada), and reacted for 2 hours with peroxidase-conjugated anti-mouse antibody (Amersham, Buckinghamshire, UK), followed by being probed with a chemiluminescence kit (Amersham).
Immunocytochemistry
RGC-5 cells grown in a chamber slide were transduced for 2 hours at an MOI of 20 pfu per cell. Forty-eight hours post-transduction, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and blocked with 2% bovine serum albumin. The cells were then incubated for 2 hours with anti-Hsp72 antibody, reacted for 2 hours with Alexa Fluor 568-conjugated goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA), and counterstained with 4',6-diamidino-2-phenylindole.
Cell viability assays
RGC-5 cells were dispensed in a 96 well plate at a concentration of 1 × 10 4 cells per well and transduced for 2 hours at an MOI of 5 and 20 pfu. The cells were washed, replenished with 100 μL of media containing 5 to 20 μM etoposide and cultured further. After 48 hours, 10 uL of reagent for used in the cytotoxicity assay (WST-8; Dojindo, Rockville, MD, USA) per well was added, and the absorbance at 450 nm was read by an automatic microplate reader after 1 hour of incubation.
Results
To express Hsp72 exogenously in RGC-5 cells that are not easily transfected by conventional methods, the cells were transduced with a recombinant adenovirus expressing human Hsp72. Western blot analysis showed that protein bands of 72 kDa corresponding to Hsp72 were clearly detected in lysates of cells transduced with a recombinant adenovirus expressing human Hsp72. The intensities of the bands were found to be in proportion to the degree of viral transduction. In untransduced control cells, a faint band equivalent to endogenous Hsp72 expression was barely detectable (Fig. 1A) . Immunocytochemistry yielded consistent results showing that cytoplasmic staining for characteristic Hsp72 expression could be detected exclusively in transduced cells but not in untransduced cells, confirming the adenovirus-mediated Hsp72 gene expression (Fig. 1B) .
To examine the effect of Hsp72 on the death of RGC-5 cells caused by apoptosis, the cells were treated with etoposide immediately after viral transduction. Compared with control cells (Fig. 2A) , early cell death was seen in a small proportion of cells in the culture without serum (Fig.  2B) , and the degree of cell death was accelerated by the treatment of etoposide (Fig. 2C) . However, the etoposideinduced cell death appeared to be blocked by Hsp72 expression, as observed by the enhanced viability of cells that were transduced immediately before etoposide treatment (Fig. 2D) . To confirm the effect of Hsp72 on the survival of RGC-5 cells, a cell proliferation assay was performed on cells treated with etoposide following viral transduction (Fig. 3) . The rate of viable cells was reduced by 44.8 ± 6.7% and 80.8 ± 9.2% relative to control cells at 5 and 20 μM etoposide, respectively. Viral transduction itself might be toxic to cells because cell viability was slightly decreased when Hsp72 was expressed in control cells. The Hsp72 expression, however, seemed to be protective to cells undergoing apoptosis in that the rate of cell death in the cultures exposed to etoposide was progressively reduced as the degree of viral transduction increased. At the highest level of Hsp72 expression, the number of viable cells recovered was increased by 24.0 ± 3.1% and 94.1 ± 10.3% over that in the control cultures at 5 and 20 μM etoposide, respectively.
Discussion
In this study, we addressed whether Hsp72 can protect RGC-5 cells from apoptotic cell death. RGC-5 cells are the only immortalized RGC cell line established to date and are used widely in glaucoma research, although it is uncertain whether the cell line is of mouse or rat origin [10] . To investigate directly the effect of Hsp72 on the death of RGC-5 cells, it is necessary to express the protein exogenously in the cells. Like other cell lines, however, RGC-5 cells show very low transfection efficiency. To overcome this obstacle, we constructed a recombinant adenovirus in which a human Hsp72 cDNA is under the control of the human cytomegalovirus promoter for its constitutive expression and demonstrated that the viral vector was successful in both transducing RGC-5 cells and expressing its transgene inside the cells. We showed that the degree of cell death by etoposide was inversely proportional to the degree of viral transduction in the cells. Etoposide, an inhibitor of topoisomerase II, is a well-known apoptosisinducing reagent [11] . Therefore, our results present direct evidence for the cytoprotective ability of Hsp72 against apoptotic cell death.
The protective role of heat shock was first described in light-damaged rat retina and Hsp72 protein was identified as the entity primarily responsible for the response [12, 13] . A growing body of evidence has accumulated that induction of Hsp72 is essential for neuronal tolerance to a Etoposide wide variety of stressful conditions including ischemic or excitotoxic insults, seizure, oxidative stress, and apoptotic stimuli [5, 8, 9] . The present study demonstrates that Hsp72 expression itself is sufficient to protect RGC-5 cells from apoptotic cell death. Apoptosis, or programmed cell death, of RGCs is one of the earlier signs of the pathogenesis of glaucoma. Because inhibition of RGC death or a halt of its progression is the key to glaucoma treatments, the ability of Hsp72 to intervene in the process of apoptosis is attractive as a novel therapeutic intervention in glaucoma. Gene therapy, which is a practical alternative to current therapies that are limited to reduction of elevated intraocular pressure, is an approach by which Hsp72 could be useful in a clinical context. Recent studies reported that Hsp72 induction by zinc or geranylgeranylacetone administration increased RGC survival in a rat glaucoma model, suggesting that Hsp72 could be therapeutic for glaucoma [14, 15] .
The eye may perhaps be the first organ for which gene therapy is used routinely in a clinical setting because it has advantages such as well-defined anatomy with small size, translucent media allowing excellent visual localization, and easy accessibility by which therapeutic agents can be delivered to the vicinity of cells with a particular defect [16] . The replication-deficient adenovirus generated in this study is a sophisticated gene delivery tool and such viralbased vectors are expected to have enormous potential as a mammalian expression system for gene therapy.
Recently, it has been reported that Hsp72 can be identified in the extracellular compartments and the extracellular Hsp72 acts as a cytokine that induces inflammation and modulates the innate immune response [17] [18] [19] [20] . The dual role of Hsp72 as a molecular chaperone and cytokine suggests that fine tuning its expression may be a potential route for a novel therapeutic approach to glaucoma and other neurodegenerative diseases.
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